Results 31 to 40 of about 47,442 (285)
JACC. CardioOncology, 2020 Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD +8 more
doaj +1 more source
Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight
Case Reports in Medicine, 2021 Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis +2 more
doaj +1 more source
SAGE Open Medical Case Reports, 2020 Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe +5 more
doaj +1 more source
Dataset on the use of 3D speckle tracking echocardiography in light-chain amyloidosis [PDF]
, 2018 The dataset presented in this article is related to the research article entitled “Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy” (Vitarelli et ...
Antonio Vitarelli +10 more
core +2 more sources
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen significant advances in disease-modifying therapies, increased awareness of CA, and improved
Lily K. Stern, Jignesh Patel
openaire +3 more sources
Transthyretin cardiac amyloidosis.
Medicine and pharmacy reports, 2021 Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca +6 more
openaire +2 more sources
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]
, 2018 PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M +8 more
core +1 more source
Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]
, 2016 Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core +2 more sources
ESC Heart Failure, 2021 Aims As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%.
Ana Devesa +10 more
doaj +1 more source
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis [PDF]
, 2016 Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is ...
Ando, Y +10 more
core +1 more source